No Data
JPMorgan Raises Price Target on Vertex Pharmaceuticals to $505 From $450, Maintains Overweight Rating
Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $589, according to analysts by Capital IQ.Price: 489.08, Change: +0.96, Percent Change: +0.20
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 2.43% HC Wainwright & Co. $462 → $500 Maintains Buy 07/11/2024 -6.79% Morgan Stanley $402 → $45
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
H.C. Wainwright analyst Andrew Fein maintains $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and adjusts the target price from $462 to $500.According to TipRanks data, the analyst has a
Express News | Vertex Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $500 From $462
Express News | Vertex Pharmaceuticals Inc : JP Morgan Raises Target Price to $505 From $450